Sugi Predict

Sugi Predict / Targets / ERBB3

ERBB3

Receptor tyrosine-protein kinase erbB-3 · P21860 · ERBB3 on Sugi Atlas →

36,202 patent compounds predicted against ERBB3, 29,402 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL986656 SCHEMBL986656 1.00 20/20
SCHEMBL983022 SCHEMBL983022 0.78 14/20
SCHEMBL8223 SCHEMBL8223 0.40 13/20
Tak-285 Tak-285 (SCHEMBL982278) 1.00 12/20
SCHEMBL986159 SCHEMBL986159 0.85 12/20
SCHEMBL985587 SCHEMBL985587 0.78 12/20
SCHEMBL984511 SCHEMBL984511 0.85 11/20
SCHEMBL984939 SCHEMBL984939 0.74 10/20
SCHEMBL986551 SCHEMBL986551 0.62 9/20
SCHEMBL1056424 SCHEMBL1056424 0.34 9/20
SCHEMBL986142 SCHEMBL986142 0.72 8/20
SCHEMBL981463 SCHEMBL981463 0.69 8/20
SCHEMBL691250 SCHEMBL691250 0.48 8/20
SCHEMBL374439 SCHEMBL374439 0.72 7/20
SCHEMBL691626 SCHEMBL691626 0.57 7/20
SCHEMBL691651 SCHEMBL691651 0.56 7/20
SCHEMBL582431 SCHEMBL582431 0.54 7/20
SCHEMBL875580 SCHEMBL875580 0.47 7/20
SCHEMBL374580 SCHEMBL374580 0.65 6/20
SCHEMBL691107 SCHEMBL691107 0.63 6/20

Clinical trials — most relevant to ERBB3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion PHASE4UNKNOWN
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,) PHASE3COMPLETED
Paclitaxel With or Without Trastuzumab in Treating Patients With or Without HER-2/Neu Breast Cancer That is Inoperable, Recurrent, or Metastatic PHASE3COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501） PHASE2RECRUITING
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer PHASE2RECRUITING
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules PHASE2UNKNOWN
Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy PHASE2COMPLETED
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer PHASE2UNKNOWN
Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene PHASE2UNKNOWN
Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma PHASE2COMPLETED
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma PHASE1/PHASE2COMPLETED
Afatinib in NSCLC With HER2 Mutation PHASE2COMPLETED
Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy PHASE2COMPLETED
Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma PHASE1COMPLETED
Assessing the Immunogenicity of pING-hHER3FL PHASE1ACTIVE_NOT_RECRUITING
Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer PHASE1UNKNOWN
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers PHASE1COMPLETED
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 PHASE1COMPLETED
Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a ERBB3 binder may also engage these)

ProteinNameSimilarity
Q5RB22 — 1.000 Q5RB22 →
Q61526 — 1.000 Q61526 →
Q62799 — 1.000 Q62799 →
Q60553 — 0.994 Q60553 →
P06494 — 0.990 P06494 →
P70424 — 0.990 P70424 →
ERBB2 Receptor tyrosine-protein kinase erbB-2 0.979 landscape →
O18735 — 0.978 O18735 →
P13388 — 0.974 P13388 →
Q01279 — 0.971 Q01279 →
P55245 — 0.968 P55245 →
P13387 — 0.968 P13387 →
P35739 — 0.967 P35739 →
Q91009 — 0.966 Q91009 →
Q3UFB7 — 0.966 Q3UFB7 →
O70309 — 0.964 O70309 →
EGFR Epidermal growth factor receptor 0.964 landscape →
NTRK1 High affinity nerve growth factor receptor 0.963 landscape →
ITGB5 Integrin beta-5 0.962 landscape →
P80747 — 0.961 P80747 →
ITGB3 Integrin beta-3 0.960 landscape →
Q9Y2I2 — 0.960 Q9Y2I2 →
Q9HCM2 — 0.959 Q9HCM2 →
Q8R4G0 — 0.959 Q8R4G0 →
O97583 — 0.959 O97583 →
P70206 — 0.958 P70206 →
O75051 — 0.958 O75051 →
Q6BEA0 — 0.956 Q6BEA0 →
Q07441 — 0.956 Q07441 →
Q9QYP2 — 0.956 Q9QYP2 →